Neurocrine provides some good news in Huntington’s
Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
The Huntington’s pipeline takes a blow
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
